T

he National Institutes of Health is staring down a proposed $6 billion budget cut that could slash funding for biomedical research. The response from the drug industry’s largest lobbying group?

Let’s call it tepid.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories